Multicenter validation of a galactomannan chemiluminescence immunoassay for the diagnosis of pulmonary aspergillosis on serum of patients with hematological disease
Journal of Clinical Microbiology · 19.02.2025 · 63 (2)
DOI: 10.1128/jcm.01053-24 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Microbiology, erschienen am 19.02.2025. Verfasst von Hanne Lamberink und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Mannans, Luminescent Measurements, Hematologic Diseases, Invasive Pulmonary Aspergillosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Selinion B.V..
Abstract (Originalsprache)
An accurate diagnosis of invasive aspergillosis (IA) in patients with underlying hematological malignancies relies heavily on galactomannan detection. In this study, we compared the VirCLIA chemiluminescence immunoassay (CLIA) with the frequently used Platelia enzyme-linked immunosorbent assay (ELISA) on serum from hematology patients with suspected IA. Patients were categorized according to EORTC/MSGERC 2020 definitions into proven/probable IA and possible/no IA. The first cohort included 161 patients at four centers, and the VirCLIA manufacturer’s cutoff of 0.200 was evaluated. Next, the optimal cutoff was determined using the Youden’s index. In a second independent cohort of 189 patients from four centers, this optimal cutoff was evaluated again. In the first cohort, sensitivities and specificities for probable/proven IA were 21.1% and 100.0% for ELISA (1.0 cutoff) and 36.6% and 95.6% (0.5 cutoff), compared to 11.3% and 97.8% for CLIA (0.200 cutoff). In the second cohort, the sensitivities of ELISA and CLIA were comparable (ELISA ≥ 1.0: 33.3%, CLIA ≥ 0.200: 38.1%). The area under the ROC curve was lower for CLIA than for ELISA in the first cohort (65.0% vs 78.7%, P = 0.005) but comparable in the second cohort (79.5% vs 81.3%, P = 0.649). Youden’s index identified 0.100 as the optimal CLIA cutoff with sensitivities of 35.2% and 61.9% in cohorts 1 and 2, respectively, at slightly reduced specificities of 85.6% and 90.5%. While the sensitivity of both assays was low to moderate at best, in patients with a high pre-test probability, we suggest 0.100 as the cutoff for the VirCLIA assay. IMPORTANCE This study demonstrates a comparable performance of the novel chemiluminescence immunoassay (CLIA) and the conventionally used enzyme-linked immunosorbent assay for galactomannan serum testing in hematological patients at high risk for invasive aspergillosis. In patients with a high pre-test probability, a lower CLIA cutoff of 0.100 is preferred.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands.
- Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands.
- Department of Hematology, Ghent University Hospital, Ghent, Belgium.
- Department of Hematology, Leuven University Hospitals, Leuven, Belgium.
- Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
- Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
ORCID-Profile: Hanne Lamberink, Sammy Huygens, Robina Aerts, Katrien Lagrou, Karin van Dijk, Ine Moors, Jerina Boelens, Marijke Reynders, Johan Maertens, Alexander Schauwvlieghe, Mireille van Westreenen, Ga-Lai M Chong, Paul E Verweij, Jochem B Buil, Bart J A Rijnders
Förderung
- Selinion B.V.
Zitieren
APA
Lamberink, H., Huygens, S., Aerts, R., Lagrou, K., van Dijk, K., Langerak, D., Moors, I., Boelens, J., Reynders, M., Maertens, J., Schauwvlieghe, A., van Westreenen, M., Chong, G. L. M., Verweij, P. E., Buil, J. B., & Rijnders, B. J. A. (2025). Multicenter validation of a galactomannan chemiluminescence immunoassay for the diagnosis of pulmonary aspergillosis on serum of patients with hematological disease. Journal of Clinical Microbiology, 63(2). https://doi.org/10.1128/jcm.01053-24
Vancouver
Lamberink H, Huygens S, Aerts R, Lagrou K, van Dijk K, Langerak D, et al. Multicenter validation of a galactomannan chemiluminescence immunoassay for the diagnosis of pulmonary aspergillosis on serum of patients with hematological disease. Journal of Clinical Microbiology. 2025;63(2). doi:10.1128/jcm.01053-24
BibTeX
@article{Lamberink2025,
author = {Lamberink, Hanne and Huygens, Sammy and Aerts, Robina and Lagrou, Katrien and van Dijk, Karin and Langerak, Diana and Moors, Ine and Boelens, Jerina and Reynders, Marijke and Maertens, Johan and Schauwvlieghe, Alexander and van Westreenen, Mireille and Chong, Ga-Lai M and Verweij, Paul E and Buil, Jochem B and Rijnders, Bart J A},
title = {Multicenter validation of a galactomannan chemiluminescence immunoassay for the diagnosis of pulmonary aspergillosis on serum of patients with hematological disease},
journal = {Journal of Clinical Microbiology},
year = {2025},
volume = {63},
number = {2},
doi = {10.1128/jcm.01053-24}
}
EUVIMED